Wednesday, February 8, 2012 Last update: 10:34 PM
The Best of U.S. Company Technology News
Now being accepted at FreshNews.com. See our complete guidelines.
Trade Events
Targacept, Inc.
News articles for Targacept, Inc.:
Monday, February 6, 2012
- Targacept Announces Participation in Upcoming ConferencesTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR TherapeuticTM, today announced that: ... read more
Thursday, January 5, 2012
- Targacept Announces Decision by AstraZeneca to Advance AZD1446 in Alzheimer’s DiseaseTargacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that AstraZeneca has informed the company that it plans to progress the ... read more
Wednesday, January 4, 2012
- Targacept to Present at the 30th Annual J.P. Morgan Healthcare ConferenceTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is ... read more
Monday, December 19, 2011
- AstraZeneca and Targacept Announce Top-line Results from Second Phase 3 Study of TC-5214 as an Adjunct Treatment in Patients with Major Depressive DisorderAstraZeneca and Targacept, Inc. today announced top-line results from the second of four RENAISSANCE Phase 3 studies investigating the efficacy and tolerability of TC-5214 as an adjunct therapy ... read more
Monday, December 5, 2011
- Targacept Announces Initiation of Two Phase 2 Studies of TC-5619Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study ... read more
Monday, November 28, 2011
- Targacept Announces Participation in Upcoming ConferencesTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is ... read more
Friday, November 11, 2011
- Targacept to Present at the Lazard Capital Markets 8th Annual Healthcare ConferenceTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is ... read more
Monday, November 7, 2011
- Targacept to Host Conference Call Today at 10:00 AM to Discuss Top-line Results from RENAISSANCE 3 Study of TC-5214 as an Adjunct to Antidepressant Treatment for Major Depressive DisorderTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), announced that Targacept management will conduct a conference call and audio webcast today at ... read more
Thursday, November 3, 2011
- Targacept Scientists to Present Data Supporting the Potential of NNR Therapeutics for the Treatment of Nervous System Diseases and DisordersTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that its scientists are scheduled to make several presentations at the 41st ... read more
Tuesday, November 1, 2011
- Targacept Reports Third Quarter 2011 Financial ResultsTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the third quarter and ... read more
Thursday, October 13, 2011
- Targacept to Present at the 2011 NewsMakers in the Biotech Industry ConferenceTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is ... read more
Monday, October 10, 2011
- Targacept Initiates a Phase 2b Study of AZD3480 in Alzheimer’s DiseaseTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of a potential registration study of ... read more